The role of the histocompatibility laboratory in desensitization for transplantation
Authors:
- Mary S LeffellMLMary S Leffell
- Andrea A ZacharyAZAndrea A Zachary
- 1 August 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 14 (4) , 398-402
Abstract
The ability of histocompatibility laboratories to define and monitor human leukocyte antigen (HLA)-specific antibodies via highly sensitive immunoassays has been a major contributing factor in the development of desensitization protocols for HLA-incompatible transplants. This review will focus on the laboratory's role in desensitization and the types of tests needed for determining the specificity and strength of antibodies to donor HLA pretransplant, during treatment, and after transplant. Increasingly, solid-phase immunoassays that use purified HLA molecules are providing sensitive characterization of HLA-specific antibodies. Assay parameters, such as median fluorescence intensity, can be correlated with cross-match results and clinical outcomes, and subsequently used to monitor antibody status in patients undergoing desensitization. The strength of donor HLA-specific antibody, measured by cross-match and/or solid phase assays, is used to determine the likelihood of successful desensitization, as well as the risk of posttransplant antibody-mediated rejection. Histocompatibility laboratories are essential components of desensitization programs. Thorough antibody characterization and serial monitoring of changes in antibody status are needed pretreatment, during treatment and after transplant. Because clinical decisions rely heavily on changes in antibody specificity and strength, desensitization should not be undertaken without access to appropriate histocompatibility testing.Keywords
This publication has 29 references indexed in Scilit:
- Detecting and monitoring human leukocyte antigen–specific antibodiesHuman Immunology, 2008
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationNew England Journal of Medicine, 2008
- Renal Transplantation in Patients With Positive Lymphocytotoxicity Crossmatches: One Center’s ExperienceTransplantation, 2008
- Clinical Relevance of Preformed HLA Donor-Specific Antibodies in Kidney TransplantationAmerican Journal of Transplantation, 2008
- Therapeutic Strategies in Management of the Highly HLA-Sensitized and ABO-Incompatible Transplant Recipients2008
- DP reactive antibody in a zero mismatch renal transplant pairHuman Immunology, 2007
- 14th International HLA and Immunogenetics Workshop: Report on understanding antibodies in transplantationTissue Antigens, 2007
- PresensitizationClinical Journal of the American Society of Nephrology, 2006
- A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific AlloantibodyAmerican Journal of Transplantation, 2006
- PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTSTransplantation, 2000